Objective. In synovial fluid (SF) from patients with rheumatoid arthritis (RA), neutrophils are exposed to proinflammatory mediators endowed with either anti-apoptotic or pro-apoptotic properties. We investigated neutrophil apoptosis in the presence of SF from 11 RA patients.
w1x. Neutrophils have also been detected at the pannuscartilage junction at sites of erosion w2, 3x, where they release potent effectors of cartilage destruction, such as serine and metalloproteases w4, 5x. In agreement with these observations, activated monocytes and fibroblastoid cells secreting interleukin (IL) 8, a major neutrophil chemoattractant, have been detected not only in the lining layer of the synovial tissue but also at the pannus-cartilage junction w6x. Thus, neutrophils have been considered to be among the cells with great potential to inflict damage within the RA joint w7x. RA fluids can also contain large quantities of immune complexes, and the deposition of immune complexes has been considered to be a major determinant of neutrophilmediated articular tissue injury w8x. Indeed, it is well known that neutrophil Fcc receptor (FccR) crosslinking by immune complexes leads to full cell activation w9x. Consequently, immune complex-activated neutrophils discharge large quantities of toxic products, overwhelming the antioxidant and antiprotease shields of synovial fluid w10, 11x. In turn, this leads to the development of tissue injury which, when relevant anduor persistent, is responsible for the irreversible anatomical destruction of the normal tissue architecture, with consequent articular dysfunction w12, 13x. More recently, it has been shown that neutrophils engaged in FccR-dependent effector functions, such as immune complex phagocytosis, undergo accelerated apoptosis w14, 15x. This is a crucial topic. It is generally accepted that neutrophil apoptosis is essential in the prevention of excessive tissue damage by decreasing the tissue load of neutrophils, neutrophil function and the histotoxic burden of neutrophils w16x. In contrast to necrotic cells, apoptotic neutrophils are promptly recognized and engulfed by macrophages without stimulating the proinflammatory activities of phagocytosing cells w17, 18x. Therefore, from a teleological point of view, immune complex-mediated apoptosis may be a mechanism to accelerate the disposal of exhausted neutrophils, thereby favouring the resolution of neutrophilic inflammation w16x. Nevertheless, proinflammatory cytokines capable of prolonging neutrophil survival are also detectable in RA synovial fluids w19-22x. Thus, the fate of neutrophils at sites of inflammation, where these cells are likely to be exposed to both anti-and pro-apoptotic influences, needs to be clarified. To investigate this issue, we studied the survival of neutrophils in the presence of articular fluids from RA joints before and after immune complex activation.
Materials and methods
Medium and reagents RPMI 1640 with 25 mM HEPES (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% fetal calf serum (FCS) (ICN Biomedicals, Milan, Italy) was used as the incubation medium. Dulbecco's phosphate-buffered saline (PBS) and Hanks' balanced salt solution (HBSS) were from Irvine Scientific. Heparin was obtained from Roche (Milan, Italy). Ficoll-Hypaque was purchased from Seromed (Berlin, Germany). Fluorescein diacetate, ethidium bromide, propidium iodide, human albumin, rabbit anti-human albumin immunoglobulin (Ig) G, ferricytochrome c, superoxide dismutase, N-ethyl-maleimide and 3,7-dimethyl-1-propargylxanthine (DMPX) were from Sigma-Aldrich (Milan, Italy). The Annexin V-FITC (FITC = fluorescein isothiocyanate) kit was purchased from Boehringer Ingelheim (Heidelberg, Germany). Human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and human recombinant IL-6 were from Genzyme (Cambridge, MA, USA). Human recombinant IL-2, human recombinant 72-amino acid IL-8, human recombinant IL-15 and human recombinant tumour necrosis factor a (TNF-a) were from Biosource International (Camarillo, CA, USA). Other reagent-grade compounds were used as obtained from commercial suppliers.
Patients
Synovial fluid was obtained after informed consent from the affected knees of 11 patients with RA diagnosed according to established criteria w23x. The mean duration of disease was 3 " 1 yr and the mean age was 51 " 8 yr. Patients (seven females, four males) were taking the following medications: non-steroidal anti-inflammatory drugs (NSAIDs; n = 9), methotrexate 7.5 mguweek (n = 2), low-dose prednisone 2.5 mguday (n = 4), auranofin 6 mguday (n = 1). No local intra-articular corticosteroid injections had been made within 5 weeks before the collection of synovial fluid samples and no patients had been treated with TNF-a blockers or leflunomide. Synovial fluid was also obtained from three patients affected with osteoarthritis (two without anti-inflammatory treatment, one taking an NSAID).
Preparation of synovial fluid samples
Immediately after synovial fluid collection, cells were counted with a haemocytometer and cytospins were prepared for the morphological assessment of apoptosis, as described below. Then synovial fluid samples were centrifuged at 1000 g for 15 min. Finally, the supernatants were removed aseptically and stored at 2208C in aliquots.
Preparation of immune complexes
Immune complexes were prepared by incubating human albumin and rabbit anti-human albumin IgG at equivalence, which was determined, on the basis of quantitative precipitin curves, at the molar ratio 1:5, as described previously w15x. Briefly, albumin and rabbit anti-human albumin IgG were incubated for 2 h at 378C and thereafter overnight at 48C. Subsequently, immune complexes were washed three times (500 g for 10 min), resuspended in cold PBS and stored at 48C. The total protein in the precipitates was determined with the Lowry assay w24x.
Neutrophil isolation and culture
Heparinized (heparin 10 Uuml) venous blood was obtained from healthy volunteers after informed consent. Neutrophils were isolated by dextran sedimentation, subsequent centrifugation on a density gradient and removal of contaminating erythrocytes by hypotonic lysis w15x. The resulting neutrophils were washed three times with incubation medium, and the final cell suspensions (2 3 10 6 uml) always contained 97% or more viable cells. Neutrophils were then incubated in tissue culture tubes (17 3 100 mm; Falcon, Becton Dickinson, Oxnard, CA, USA) at 378C in a 5% CO 2 atmosphere (final volume 0.5 ml). Experiments were carried out in the absence or presence of immune complexes (25 mguml), GM-CSF (10 nguml), IL-2 (1000 Uuml), IL-6 (1000 Uuml), IL-8 (10 nguml), IL-15 (10 nguml) or TNF-a (10 nguml). The concentrations of immune complexes, chemokines and cytokines were chosen on the basis of preliminary dose-response experiments (data not shown). At appropriate time points, cells were harvested and counted on a haemocytometer before subsequent assays.
Neutrophil membrane integrity assay Neutrophil viability, measured as the integrity of the cell membrane, was assessed according to Dankberg and Perdisky w25x as described previously w15x. Briefly, cells (4 3 10 4 u100 ml) harvested from culture tubes were mixed with 50 ml of staining solution (2 mguml fluorescein diacetate, 4 mguml ethidium bromide in HBSS) and incubated for 10 min at room temperature. Thereafter, a drop of cell suspension was placed on a slide, sealed with a coverslip and analysed under ultraviolet light with dark-field illumination. Neutrophils with an intact membrane (i.e. viable cells) appeared as green fluorescent cells, whereas neutrophils with a damaged and ethidium bromide-permeable membrane (i.e. necrotic cells) displayed a fluorescent red nucleus.
Light microscopic assessment of neutrophil apoptosis Cytocentrifuged cell preparations were fixed and stained with May-Grü nwald-Giemsa. Thereafter, two independent observers read cytopreparations blindly by oilimmersion light microscopic examination of at least 500 cellsuslide (magnification 1000 3 ). Cells showing apoptotic morphology were identified according to the typical criteria of cell shrinking, nuclear condensation and fragmentation, plasma membrane ruffling and blebbing w26x, as described previously w15x.
Immunofluorescence flow cytometry of annexin V-FITC binding Immunofluorescence analysis of annexin V binding was performed with the Annexin V-FITC Kit according to the manufacturer's instructions with minor changes, as described previously w15x. Briefly, cells were washed and resuspended in 100 ml isotonic binding buffer. Then annexin V-FITC (3 ml) was added and, after incubation (15 min), cells were washed and resuspended in ice-cold PBS supplemented with 3% FCS and 0.1% sodium azide. Flow cytometry analysis was performed on an EPICS XL flow cytometer (Coulter, Hialeah, FL, USA). Living granulocytes were gated on the basis of physical properties (forward vs side light scatter) and at least 2000 living cells were analysed for each sample. Flow cytometer settings for the gating and analysis of neutrophils were adjusted in conformity with results from preliminary experiments performed on CD15-stained purified neutrophils.
Superoxide anion release assay
The release of superoxide anion was studied by using a modification of the method of Babior et al. w27x as described previously w28x. Briefly, neutrophils (5 3 10 5 ) were incubated (20 min, 378C, final volume 0.5 ml) with 80 mM ferricytochrome c in the absence or presence of 300 Uuml superoxide dismutase (SOD). The reactions were then stopped by adding 2 ml of ice-cold 1 mM N-ethyl maleimide and superoxide production was determined in the supernatants from the optical density at 550 nm (OD 550 ) of samples without SOD minus the OD 550 of samples with SOD, using an extinction coefficient of 2. Determination of GM-CSF and TNF-a levels in synovial fluid samples Synovial fluid samples were filtered on pore size 0.8 mm (Millipore S.p.A., Vimodrone, Italy) and treated with 150 Uuml hyaluronidase (Sigma). After incubation (20 min, 378C), the concentrations of GM-CSF and TNF-a were measured by immunoassays from Medgenix Diagnostics (Fleurus, Belgium) (GM-CSF) and BioSource (TNF-a).
Determination of adenosine levels in synovial fluid samples Adenosine levels in synovial fluids were determined chromatographically, as detailed elsewhere w29x. The chromatographic analyses were performed with a Perkin-Elmer (Norwalk, PA, USA) Model Series 4 liquid chromatograph, a Rheodyne 7125 (Berkeley, CA, USA) injector valve with a 10 ml loop, and a PerkinElmer model LC35 diode-array UV detector. Retention times, peak areas and UV spectra were recorded with a Perkin-Elmer LCI-100 integrator. A 250 3 4.6 mm internal diameter stainless-steel Hibar column prepacked with 5 mm RP-18 phase was used (Hypesil, Runcorn, UK); the column was protected with a LiChroCart 4-4 guard cartridge system (Merck, Darmstadt, Germany). The mobile phase consisted of acetonitrile-0.01 M monobasic sodium phosphate (5:95 vuv), and it was delivered with a high-pressure solvent-mixing valve. The flow rate was 1.0 mlumin. Detection was performed at 260 nm. All separations were carried out at room temperature. Calibration curves were constructed by plotting the peak area of standard working aqueous solutions of adenosine (y) against concentration (x) using linear regression analysis w29x. Unknown concentrations of adenosine were quantified by relating the respective peak area to the regression line.
Determination of immune complex levels in synovial fluid samples
The concentrations of immune complexes in synovial fluids were measured with an immunoassay from Dia.Metra, Segrate-Milano, Italy, according to the manufacturer's instructions.
Immunodepletion of cytokines in synovial fluid
Synovial fluid samples were immunodepleted of GM-CSF and TNF-a singly and of GM-CSF and TNF-a together, by adding to the synovial fluid the appropriate neutralizing polyclonal antibodies (60 mguml; Genzyme, Cambridge, MA, USA). The antibody concentration was chosen in order to achieve >90% neutralization of cytokine activity, on the basis of neutralization assays performed by the manufacturer. After incubation (overnight, 48C), synovial fluids were ultracentrifuged (10 000 g, 45 min). After immunodepletion, the cytokines were undetectable in all samples, as measured by the above-mentioned immunoassays. Therefore, supernatants were tested immediately in the apoptosis assay, as described above.
Statistical analysis
Data were expressed as mean " S.D. Analyses were performed with GraphPad Instat and GraphPad Prism (GraphPad Software, San Diego, CA, USA).
Differences were determined by one-way analysis of variance with Bonferroni multiple comparison tests. Correlations between pairs of variables were assessed by the Pearson method. Differences were accepted as significant when P < 0.05.
Results
Effect of RA synovial fluids on neutrophil apoptosis The effects of RA synovial fluids on neutrophil apoptosis were studied in two experimental conditions: (i) spontaneous apoptosis evaluated after 18 h in vitro incubation and (ii) apoptosis of immune complexactivated neutrophils after 12 h of incubation. The time-points were chosen on the basis of our previous observations w15x to allow detection of inhibition as well as acceleration of the apoptotic process. Neutrophils from normal donors were incubated in the absence or presence of 50% synovial fluid for the appropriate period of time, then apoptosis was determined morphologically.
As shown in Fig. 1 , neutrophil apoptosis was significantly reduced by co-incubation with eight of 11 synovial fluids obtained from inflamed joints of distinct RA patients. This was observed in both spontaneous (Fig. 1A) and immune complex-stimulated (Fig. 1C) neutrophil apoptosis. Moreover, as shown in Table 1 One-way analysis of variance, P < 0.0001. Bonferroni multiple comparison test for patients 1 (n = 9), 4 (n = 7), 5 (n = 8), 7 (n = 4), 8 (n = 4), 9 (n = 4), 10 (n = 4) and 11 (n = 4), apoptosis in the absence vs presence of synovial fluid, P < 0.001; patients 2 (n = 6), 3 (n = 6) and 6 (n = 3), apoptosis in the absence vs presence of synovial fluid, P > 0. samples showed an evident anti-apoptotic action from the 6 h time point of neutrophil ageing. The inhibitory activity of the eight synovial fluids was dose-dependent in both systems (not shown). In all cases, neutrophil viability, assessed as membrane integrity, was more than 97%. Similar results were obtained in selected experiments using autologous neutrophils purified from peripheral blood of RA patients (data not shown).
Effect of proinflammatory cytokines on neutrophil apoptosis Neutrophil apoptosis can be modulated by several soluble ligands, including cytokines detectable at sites of inflammation w19-22x. In an attempt to identify the factor(s) responsible for the anti-apoptotic activity of synovial fluids, the effects of six cytokines on spontaneous and immune complex-induced neutrophil apoptosis were studied. Neutrophils were incubated in the absence or presence of GM-CSF (10 nguml), IL-2 (1000 Uuml), IL-6 (10 nguml), IL-8 (10 nguml), IL-15 (10 nguml) or TNF-a (10 nguml). The concentration of each cytokine was chosen on the basis of preliminary dose-response experiments (not shown). After the appropriate incubation time, apoptosis was determined morphologically and confirmed, using a flow cytometer, by the annexin V binding assay. As shown in Fig. 2 , a significant reduction in the percentage of spontaneous apoptosis was observed in the presence of GM-CSF, IL-6, IL-15 or TNF-a, but not of IL-2 or IL-8.
Furthermore, only GM-CSF and TNF-a displayed anti-apoptotic properties with respect to immune complex-dependent neutrophil apoptosis (Fig. 3) . We did not observe anti-apoptotic activity even when the inactive ligands were used at 100-fold higher concentration (data not shown). Taking into account the fact that reports about the effects of TNF-a on neutrophil apoptosis are conflicting, some indicating that this cytokine has pro-apoptotic activity and others that it has an anti-apoptotic role w30-34x, we performed a series of time-course and dose-response experiments. As reported in Table 2 , TNF-a exerted a slight proapoptotic effect at earlier time-points (at 3 and 6 h for spontaneous apoptosis and at 3 h for immune complex-induced apoptosis), whereas potent anti-apoptotic activity was observed at subsequent time-points. Finally, the capacity of TNF-a to retard neutrophil ageing was confirmed in dose-response experiments, as shown in Table 3 .
Inhibition of neutrophil apoptosis by synovial fluids does not depend on GM-CSF and TNF-a
The results reported above suggest that the inhibition of spontaneous and immune complex-stimulated neutrophil apoptosis by synovial fluids may depend on the presence of GM-CSF anduor TNF-a in the articular effusions. Consequently, we determined the synovial fluid concentrations of GM-CSF and TNF-a. Both cytokines were detected in the 11 fluids examined, at concentrations ranging from 0.5 to 28.1 pguml for TNF-a and from 0.9 to 414.0 pguml for GM-CSF. Nevertheless, no relationship was found between the GM-CSF and TNF-a concentrations measured in each synovial fluid studied and the levels of neutrophil apoptosis detected in the presence of the same synovial fluid (Fig. 4) . Accordingly, immunodepletion of GM-CSF and TNF-a had no effect on the anti-apoptotic activity of synovial fluids (data not shown).
Inhibition of neutrophil apoptosis by synovial fluids depends on adenosine
Two recent reports suggest that neutrophil apoptosis can be down-modulated by adenosine w35, 36x, a ubiquitous autacoid endowed with immune-modulatory properties towards several cell types, including neutrophils w37, 38x. Evidence for the anti-apoptotic activity of adenosine was obtained by using adenosine analogues and selective adenosine receptor agonists w35, 36x; at present there is no direct evidence for neutrophilic antiapoptotic activity of adenosine. Thus, a series of experiments was planned to investigate the possible role of adenosine in the observed activity of RA synovial fluids on neutrophil apoptosis. We found that adenosine was capable of slowing the rate of spontaneous apoptosis of neutrophils incubated for 18 h wmean (S.D.) inhibition of neutrophil apoptosis in the presence of 10 mM adenosine, 18.1 " 17.8%, n = 5; inhibition of neutrophil apoptosis in the presence of 100 mM adenosine, 31.1 " 17.7, n = 5x. We then verified the anti-apoptotic activity of synovial fluids morphologically and by flow cytometry (annexin V binding assay) in the absence or presence of 0.25 Uuml adenosine deaminase, an enzyme capable of removing efficiently any adenosine that is present in the samples. The capacity of each synovial fluid to slow the apoptotic process was almost completely abolished by the treatment with adenosine deaminase. This was observed for both spontaneous apoptosis (Fig. 5) and immune complex-induced apoptosis (Fig. 6) . Similar results were obtained by using DMPX, an antagonist of the adenosine A 2 receptor (data not shown). No effect was observed when adenosine deaminase was added to neutrophils in the absence of synovial fluid, ruling out the direct pro-apoptotic activity of the enzyme (data not shown). Consequently, adenosine levels in synovial fluids were determined chromatographically. In eight samples, adenosine was detected at concentrations ranging from 18.7 to 52.4 mM. After the addition of adenosine deaminase, the adenosine signal disappeared (not shown). On the contrary, in the remaining synovial fluids (n = 3) adenosine was undetectable, but a readily detectable peak was found after the addition of 2.6 mM adenosine (not shown). Consistent with these findings, the adenosine levels detected in each synovial fluid correlated significantly with their anti-apoptotic activity towards normal neutrophils (r 2 = 0.8818, P < 0.0001) (Fig. 7A ) and the number of apoptotic neutrophils detected in the same sample (r 2 = 0.7017, P < 0.005) (Fig. 7B) . On the contrary, no correlation was found between adenosine level and immune complex concentrations measured in each synovial fluid sample by immunoassay (data not shown). Finally, the anti-apoptotic properties of three pauci-inflammatory synovial fluids from different patients affected by osteoarthritis were studied. As shown in Table 4 , neutrophil ageing was unaffected by co-incubation with synovial fluids. Consistent with this, adenosine was undetectable in all three samples.
Effect of RA synovial fluids on neutrophil activation by immune complexes Immune complexes are well-known activators of neutrophil oxidative metabolism. On the other hand, adenosine is currently considered a natural anti-inflammatory compound, capable of down-regulating neutrophil activation w38x. Therefore, we evaluated the capacity of synovial fluids to modulate the neutrophil activation triggered by immune complexes. As shown in Fig. 8 , synovial fluids were found to be incapable of interfering with neutrophil activation, evaluated as superoxide anion production.
Discussion
In the present study, we show that (i) neutrophil survival is significantly prolonged in the presence of inflammatory synovial fluids from patients affected by RA; (ii) RA synovial fluids are also capable of slowing the rate of apoptosis of neutrophils engaged in FccR-dependent effector functions, i.e. immune complex phagocytosis; and (iii) the exposure of immune complex-triggered neutrophils to synovial fluid does not impair the capacity of these cells to mount an efficient functional response, measured as superoxide anion production. In other words, we provide the first evidence that the activation-induced acceleration of neutrophil apoptosis can be overwhelmed and countered by anti-apoptotic influences present in RA synovial fluid, which in turn does not affect the capacity of neutrophils to undergo full activation. Taking into account the observation that apoptosis of neutrophils limits their histotoxic potential by favouring removal of these cells from inflamed tissue w16x, we propose that the microenvironment of RA synovial fluid is a proinflammatory milieu that is responsible, at least in part, for the persistence of activated and long-surviving neutrophils in the inflamed RA joint.
In 1995, Bell et al. showed that inflammatory synovial fluid contains unidentified factorus capable of promoting neutrophil apoptosis w39x. We have no explanation for these contrasting conclusions. Like Bell et al., we studied synovial fluid from patients taking different medications and no correlation was found among the different groups of patients, rendering unlikely the possibility that the differences between the studies can be related to drug-mediated effects. On the other hand, our findings are in agreement with recent reports showing retardation of the spontaneous apoptosis of neutrophils during pathological conditions characterized by neutrophilic inflammation, i.e. acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS) and ulcerative colitis w40-43x. In particular, it has been shown that biological fluids from ARDS and SIRS patients delay neutrophil apoptosis through the anti-apoptotic activity of selected cytokines, such as GM-CSF and TNF-a w40-42x. Exploring this possibility, we found that, among the cytokines investigated, only recombinant GM-CSF and TNF-a are capable of inhibiting spontaneous as well as immune complexmediated apoptosis of normal neutrophils in vitro. Although Salamone et al. w34x showed a profound increase in neutrophil apoptosis after exposure to TNF-a, our results are in accord with previous studies indicating anti-apoptotic activity for this cytokine and, in particular, with data from Murray et al. w31x showing early accelerated apoptosis only in a subpopulation of neutrophils. These contrasting data are the subject of intense scientific discussion, but we did not investigate this issue further, taking into account that inhibition of neutrophil apoptosis by synovial fluids does not depend on TNF-a. Indeed, although we detected TNF-a as well as GM-CSF in RA synovial fluids, we were unable to demonstrate that the anti-apoptotic properties of synovial fluids depend on the presence of these cytokines. Conversely, we provide evidence that the synovial fluidinduced modulation of neutrophil survival is mediated by its adenosine content. This is suggested by the following findings: (i) reagent adenosine is capable of inhibiting neutrophil apoptosis in vitro; (ii) adenosine concentrations strictly correlate with the anti-apoptotic activity of synovial fluid towards normal neutrophils; (iii) adenosine concentrations strictly correlate with the number of apoptotic neutrophils detected in synovial fluids; and (iv) the anti-apoptotic activity of synovial fluids is completely abrogated by adenosine deaminasemediated depletion of adenosine content. Thus, the ex vivo neutrophilic anti-apoptotic activity of adenosine demonstrated in the present work confirms and extends previous observations obtained in vitro w35, 36x.
Adenosine is an endogenous nucleoside released by a variety of normal, stimulated and injured cell types. It is a normal constituent of blood, where it has been detected at concentrations ranging from 20 to 300 nM w44, 45x, well below the concentrations we observed in RA synovial fluids. This is not a surprising finding in view of the short plasma half-life of adenosine w46x, which is due to its rapid uptake by blood cells, primarily erythrocytes w47x. On the other hand, it is conceivable that, in the extravascular compartment, i.e. in the absence of red cells, the rate of adenosine uptake could be slower and consequently the concentration of the autacoid could be higher. Although few data regarding extravascular adenosine levels are available, in accord with the present findings, adenosine has been measured in alveolar and pericardial fluids at concentrations ranging from to 1 to 200 mM w48, 49x.
Adenosine is considered a major modulator of the immune system, endowed with anti-inflammatory properties by acting on different target cells, including neutrophils w37, 38x. Using an ex vivo model of a typical neutrophilic inflammatory disease, i.e. RA, we outline a different scenario. We show that, in the majority of RA synovial fluids examined, all of which were characterized by active neutrophilic inflammation, adenosine was detectable at concentrations capable of inhibiting apoptosis of neutrophils, which in turn were fully susceptible to the induction of activation. This suggests that adenosine is likely to display in vivo weak or negligible capacity to inhibit the activation of the neutrophils recruited in the inflamed joint. This is consistent with previous findings showing that adenosine is a poor down-modulator of oxidant production by neutrophils triggered with immune complexes w50x. On the other hand, the presence of soluble factors endowed with neutrophil-priming properties, i.e. GM-CSF and TNF-a, may contribute to the lack of inhibitory activity of adenosine-rich synovial fluids. Accordingly, neutrophils with an activated phenotype are detectable in synovial fluids of RA patients w51x, where they are responsible for the inactivation of intra-articular proteinase inhibitors w11x and contribute to the appearance of cartilageubone erosions w5x.
Methotrexate, one of the most widely used antirheumatic drugs in the treatment of RA, augments the extracellular release of adenosine, which in turn may contribute to the anti-inflammatory activity of the drug w52x. In particular, several pieces of experimental evidence hint that this drug may exert even neutrophiltargeted anti-inflammatory activities. Indeed, Cronstein et al. w53x found that adenosine released from endothelial cells treated with methotrexate inhibits efficiently the adhesion of activated neutrophils. Furthermore, oral administration of low doses of methotrexate inhibits murine leucocyte recruitment at the site of inflammation by an adenosine-dependent mechanism w54x. Finally, treatment with methotrexate inhibits migration and articular recruitment of neutrophils in patients with RA w55x. Hence, as far as neutrophils are concerned, we propose that the anti-inflammatory activity of methotrexate is probably due to the inhibition of neutrophil recruitment at sites of inflammation, as evidenced by these reports w53-55x, without affecting the susceptibility to activation of the recruited cells, as suggested by the present results. On the contrary, the anti-apoptotic activity of adenosine-containing synovial fluids shown in the present work may offer further possible clues about the incomplete or delayed therapeutic responses observed during treatment with methotrexate. From a broader point of view, the variable concentrations of adenosine in RA synovial fluids found in the present work might explain, on the basis of the neutrophil antiapoptotic activity of the autacoid, the different intensities of synovial neutrophilic inflammation and the possibly different therapeutic responses in different RA patients, as reviewed recently w56x.
Due to the relatively small number of synovial fluid samples studied, our results do not offer proven explanations for the differences observed between adenosine levels (and the related anti-apoptotic activity) in 11 samples of RA synovial fluid. Nevertheless, some observations can be made. (i) Although various antirheumatic drugs, including methotrexate and salicylate w52, 57x, have been reported to affect adenosine release, under our experimental conditions no correspondence was found between drug treatment and adenosine levels in the corresponding synovial fluids. In particular, adenosine was undetectable in synovial fluid from one of two patients under methotrexate treatment. Similarly, adenosine was not detected in patients taking NSAIDs (two with RA and one with osteoarthritis). (ii) It has been reported that TNF-a is capable of inhibiting adenosine release from some types of cell, including adipocytes w58x. Furthermore, adenosine is capable of inhibiting TNF-a production from activated neutrophils w59x. Nevertheless, no correlation was found between TNF-a and adenosine levels in synovial fluids. (iii) None of the three pauci-inflammatory synovial fluids exerted anti-apoptotic activity and accordingly adenosine could not be detected in them. Nevertheless, much more investigation is needed in order to conclude that the adenosine effects we observed are related to the degree of articular inflammation.
The identification of rational targets for the pharmacological manipulation of neutrophil apoptosis is currently under intensive investigation w60-62x. Our results suggest that the design of therapeutic strategies to increase the rate of neutrophil apoptosis during neutrophilic inflammation should take into account the multiple microenvironmental influences to which neutrophils are exposed in vivo.
